Phenomics Australia in partnership with Therapeutic Innovation Australia (TIA), and the National Deuteration Facility (NDF), is thrilled to announce the successful recipients of the Pipeline Accelerator 2024-25 (Round 1).
Supported through the National Collaborative Research Infrastructure Strategy (NCRIS) program, this initiative helps address the medical products challenge outlined in the 2021 National Research Infrastructure Roadmap. Together, Phenomics Australia, TIA, and NDF provide academic researchers and SMEs access to world-class Australian translational medical research infrastructure, spanning the molecular basis of health and disease to clinical trials.
This round, 37 projects will share a total of $1,263,387 in voucher awards with a total cash co-investment fund of $1,316,674, facilitating access to national research infrastructure (NRI) to accelerate therapeutic translation and improve human health. Supported research areas include kidney, heart, cancer, and infectious diseases. These vouchers will subsidise a maximum of $50,000 of the total cost to access these translation NRIs.
Eleven recipients were awarded with the Phenomics Australia Pipeline Accelerator 2024-25 (Round 1) and are listed below. Among the recipients, we would like to highlight Dr Aude Dorison’s (Murdoch Children’s Research Institute)’s project on screening for new treatments for glomerular disease with a new stem cell reporter line. This project is jointly supported by the Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) (Phenomics Australia) and Drug Discovery Facility (TIA).
Notably, several recipients are continuing their journey with us – a testament to its impact and value in advancing therapeutic research. For instance, Dr Denny Cottle from Monash Biomedicine Discovery Institute has previously received support from TIA and in this round is receiving support from Phenomics Australia, highlighting the sustained value of these initiatives.
Phenomics Australia’s Pipeline Accelerator awards:
Click here to see the TIA voucher recipients.
The 11 recipients of the Phenomics Australia Pipeline Accelerator 2024-25 (Round 1) are listed below:
Click on the image to see the Phenomics Australia node involved
Dr Aakanksha Dixit (The University of Queensland)
Phenomics Australia node: Monash Genome Modification Platform (Monash)
Developing a humanized mouse model for Multiple Sclerosis
Dr Alexander Maytum (Murdoch Children’s Research Institute)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Studying enhancer function and the genetics of blood cell development from human induced pluripotent stem cells
Dr Aude Dorison (Murdoch Children’s Research Institute)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
TIA node: Drug Discovery Facility
Screening for new treatments for glomerular disease with a new stem cell reporter line
Dr Caitlin Finney (Westmead Institute for Medical Research)
Phenomics Australia node: Victor Chang Stem Cell Production Facility (VCCRI)
Testing precision medicines for Alzheimer's disease using advanced 3D human brain models
Dr Charlene M Magtoto (Walter and Eliza Hall Institute of Medical Research)
Phenomics Australia node: Melbourne Advanced Genome Editing Centre (ONJCRI/WEHI)
Creating an immunocompetent preclinical prostate cancer model to investigate targeting a tumour-driving transcription factor to stop disease
Dr Denny Cottle (Monash Biomedicine Discovery Institute)
Phenomics Australia nodes: Monash Genome Modification Platform (Monash)
Developing rapid Pharmacodynamic AURKA Targeted Protein Degrader screening mice
Dr James McNamara (Murdoch Children's Research Institute)
Phenomics Australia nodes: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI) and Melbourne Advanced Genome Editing Centre (ONJCRI/WEHI)
Developing novel models of cardiomyopathy for therapeutic testing
Dr Katharine Goodall (Murdoch Children's Research Institute)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Gene therapy to cure primary immunodeficiencies
Dr Lachlan Jolly (The University of Adelaide)
Phenomics Australia node: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility (MCRI)
Overcoming Silence in Neurodevelopmental Disorder Gene Diagnosis
Dr Lauren Elizabeth Bleakley (Florey Institute of Neuroscience and Mental Health)
Phenomics Australia node: Monash Genome Modification Platform (Monash)
Engineering genetic mouse models of severe childhood epilepsy to test the efficacy of venom peptides as a therapeutic strategy
Dr Sara Hlavca (Monash University)
Phenomics Australia node: Victorian Centre for Functional Genomics (PeterMac)
Identifying patient-specific treatments that target plasticity in colorectal cancer via high throughput screening
Contact us to know more about this voucher scheme that aims to support therapeutic development projects by providing up to $50,000 with at least 50% matching co-investment to be provided by the applicant.
Phenomics Australia and TIA are two of the six members of NCRIS Health Group that works closely with each other and provide seamless access to world-class health and medical research infrastructure and expertise.
